Tianning Yu

PhD Candidate in Immunology at University of Toronto

[Sholto David @addictedtoigno1]

Today I am sharing a new preprint and accompanying blog post. Hundreds of published papers include impossible western blots showing protein expression in cell lines that have deleted or mutated genes. These clumsy mistakes are widespread and repeated by LLMs.

[matsubayashi @Matsubayashi_J]

How to write a rebuttal letter
Nature Methods, Editorial
https://t.co/pVg2zR7R29

[Nature Rev Immunol @NatRevImmunol]

The next big questions in immunology https://t.co/JPTwmdi9Ej

[Waggoner Lab @LabWaggoner]

Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors @NatureComms @GuermonprezLab @institutpasteur 🇫🇷a
https://t.co/1n6DP2Ji6K

[Cristina Muñoz Pinedo @crismunozp]

I like it when the beef ends up being a paper in a decent journal.

Cell versus PNAS.

"Direct activation of SARM1 by dsDNA is not supported by biochemical and cellular evidence"
https://t.co/xcj22pz8g3

[Nature Rev Immunol @NatRevImmunol]

Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization https://t.co/M7z8qvUlJN

[Waggoner Lab @LabWaggoner]

Intratumoral T cell activation kills tumors regardless of T cell specificity @NatImmunol @oliviacs_ @umnmstp
@masopust_vezys @cfi_umn @Noah_V_Gavil
https://t.co/t00LvbVd24

[Waggoner Lab @LabWaggoner]

Some inflammatory monocytes differentiate into lung-resident Gal-1+ myeloid cells that colocalize with & support the long-term maintenance/recall responses of influenza virus-induced tissue-resident memory CD8 T cells @NatImmunol
https://t.co/6bRwyC9kHy
https://t.co/tcm48hzxUs

[Waggoner Lab @LabWaggoner]

Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells @FrontiersIn
https://t.co/4814GbgEER

[David Usharauli @3DiMMUNE]

In my view, from the perspective of adaptive immunity, responses to self and to chronic infection are fundamentally indistinguishable. Autoimmunity is an obvious failure of tolerance, and chronic infection should be viewed similarly.

#immunology

1/5

https://t.co/X9eb3Ux8ua

[Waggoner Lab @LabWaggoner]

A mechanosensitive ion channel regulates liver cell proliferation after injury @ScienceMagazine 🇨🇳
https://t.co/bpwbhzrxUe
https://t.co/aiMFp54h2q

[Nature Rev Immunol @NatRevImmunol]

Glycolytic capacity instructs tumour vasculature and response to immunotherapy https://t.co/TjsS0gLSke

[Waggoner Lab @LabWaggoner]

LEF1 and niche-derived factors are identified as essential regulators of T cell stemness across chronic diseases @CellCellPress @MSKCancerCenter @SchietingerLab @dbetel @katrinamhawley et al
https://t.co/TxJPxyj3VH

[Waggoner Lab @LabWaggoner]

Intratumoral Treg cell ablation drives NK cell tumor control via CD4 T conv cell–derived IL-2, eliminating MHC I+ or MHC I− cancers without systemic toxicity
https://t.co/YfUsOYivpj @SciImmunology @UCBerkeley @david_raulet

[Miriam Merad, MD, PhD @MiriamMerad]

This is an important read - and a key response to this challenge is to concentrate resources on early trials for the deep molecular profiling of responses to novel therapies- and advance programs only if biology aligns with pathological/clinical responses

[nature @Nature]

Nature research paper: DNA damage burden causes selective CUX2 neuron loss in neuroinflammation

https://t.co/fdCfFcwbHd

[Dr. Thomas Ichim @exosome]

Lack of MHC I makes target cells susceptible to CD4 T cell killing

Dogma busted ! Nature paper

$ibrx #anktiva

https://t.co/s889gaX4EP

[Immunity @ImmunityCP]

Online now: Foxp3 and BATF cooperatively direct cis-regulatory programs and gene expression for effector Treg cell differentiation https://t.co/DUpSIbBY5Y

[Claudia Jakubzick @claudjak]

Excited to share- Building on our work defining TRMacs heterogeneity, we show that distinct chemokine+ IM subsets and recruited TAM niches shape pro- and anti-tumor immunity within to the TME, while Ag+ moDCs trafficking to LNs dampen DC-based neoAg vac
https://t.co/iYpHv6O1S4

[ACIR @ACIR_org]

Genetic studies by Li et al. showed that SLAMF6 (also known as Ly108) functioned to repress T cell activation in mice and humans by triggering homotypic cis interactions at the T cell surface, suppressing TCR signaling through SHP-1 and limiting antitumor immunity, independent of SLAMF6 expression on tumor cells or APCs. SLAMF6 was expressed preferentially on Tpex cells, but not terminally exhausted Tex cells, and potent agonist mAbs that blocked T cell SLAMF6 cis binding boosted T cell activation and increased antitumor T cell responses, decreased numbers of Tex cells, and inhibited tumor growth in vivo, comparable to results obtained with SLAMF6 deficiency. https://t.co/ld73rMvzxM  @mcgillu